Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers will collaborate on research and development of a Bcl-2 protein antagonist and VEGFR-based kinase inhibitor.
You may also be interested in...
Start-up BiPar Seeks Fast Track In PARP Inhibition
Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.
Start-up BiPar Seeks Fast Track In PARP Inhibition
Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.
Genta To File Complaint With FDA Over Statistical Analysis Of Genasense Data
Complaint relates to 2004 analysis of Genasense progression-free survival data in melanoma, presented to the Oncologic Drugs Advisory Committee.